Subcutaneous Drug Development & Delivery Consortium Inc
EIN: 850837695 · Beaverton, OR · NTEE: S46
| Metric | Value |
|---|---|
| Total Revenue | $722K |
| Total Expenses | $769K |
| Net Assets | $626K |
Is Subcutaneous Drug Development & Delivery Consortium Inc Legit?
Insufficient Data
Assessment based on IRS 990 filings, spending patterns, and AI analysis. Not a guarantee of legitimacy. Full charity check →
About Subcutaneous Drug Development & Delivery Consortium Inc
Subcutaneous Drug Development & Delivery Consortium Inc (EIN: 850837695) is a nonprofit organization based in Beaverton, OR, classified under NTEE code S46. The organization reported total revenue of $722K and total assets of $1.2M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Subcutaneous Drug Development & Delivery Consortium Inc's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.
Organization Overview
Subcutaneous Drug Development & Delivery Consortium Inc is a small nonprofit that has been operating for 4 years, with 4 years of IRS 990 filings on record (2020–2023). Revenue has grown at a compound annual rate of 15.0%.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
| Total Revenue | $760K |
| Total Expenses | $769K |
| Surplus / Deficit | $-9,199 |
| Total Assets | $901K |
| Total Liabilities | $276K |
| Net Assets | $626K |
| Operating Margin | -1.2% |
| Debt-to-Asset Ratio | 30.6% |
| Months of Reserves | 14.1 months |
Financial Health Grade: B
In 2023, Subcutaneous Drug Development & Delivery Consortium Inc reported a deficit of $9K with expenses exceeding revenue, holds 14.1 months of operating reserves (strong position), has a debt-to-asset ratio of 30.6% (moderate leverage).
Financial Trends
Over 4 years of filings (2020–2023), Subcutaneous Drug Development & Delivery Consortium Inc's revenue has grown at a compound annual growth rate (CAGR) of 15.0%.
| Year | Revenue Change | Expense Change | Asset Change |
|---|---|---|---|
| 2023 | +87.1% | +43.0% | +31.4% |
| 2022 | -32.3% | +91.9% | -21.0% |
| 2021 | +20.0% | +427.6% | +19.5% |
IRS Tax-Exempt Classification
| IRS Classification Codes | 1000 |
| IRS Ruling Date | 2022 |
Classification data from ProPublica Nonprofit Explorer. Additional BMF data may be available after enrichment.
AI Analysis Pending
AI enrichment for Subcutaneous Drug Development & Delivery Consortium Inc has not yet been completed. Basic IRS 990 data is shown below. Check back later for a full transparency report including a Mission Score, spending breakdown, executive compensation analysis, and red flags assessment.
Mission Effectiveness Score
NonprofitSpending's AI analysis rates Subcutaneous Drug Development & Delivery Consortium Inc with a Mission Score of 0 out of 100 (Very Poor). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
- The organization reported a deficit of $9K, with expenses exceeding revenue.
- Debt-to-asset ratio: 30.6%.
Frequently Asked Questions about Subcutaneous Drug Development & Delivery Consortium Inc
Is Subcutaneous Drug Development & Delivery Consortium Inc a legitimate charity?
Based on AI analysis of IRS 990 filings, Subcutaneous Drug Development & Delivery Consortium Inc (EIN: 850837695) insufficient data. 0 red flags identified, 0 strengths noted.
How does Subcutaneous Drug Development & Delivery Consortium Inc spend its money?
Detailed spending breakdown data is not yet available for Subcutaneous Drug Development & Delivery Consortium Inc. Check back for updated IRS 990 analysis.
Are donations to Subcutaneous Drug Development & Delivery Consortium Inc tax-deductible?
Subcutaneous Drug Development & Delivery Consortium Inc is registered as a tax-exempt nonprofit (EIN: 850837695). Donations to most 501(c)(3) organizations are tax-deductible. Consult a tax professional for your specific situation.
Where is Subcutaneous Drug Development & Delivery Consortium Inc located?
Subcutaneous Drug Development & Delivery Consortium Inc is headquartered in Beaverton, Oregon and files with the IRS under EIN 850837695. It is classified under NTEE code S46.
How many years of IRS 990 filings does Subcutaneous Drug Development & Delivery Consortium Inc have?
Subcutaneous Drug Development & Delivery Consortium Inc has 4 years of IRS 990 filings on record at NonprofitSpending. Additional filing years may become available as the IRS releases new data. The most recent filing shows $722K in total revenue.
Filing History
IRS 990 filing history for Subcutaneous Drug Development & Delivery Consortium Inc showing financial trends over 4 years of public records:
Over 4 years of IRS 990 filings (2020–2023), Subcutaneous Drug Development & Delivery Consortium Inc's revenue has grown by 52%, moving from $500K to $760K. Total assets increased by 24% over the same period, from $727K to $901K. Total functional expenses rose by 1347.4%, from $53K to $769K. In its most recent filing year (2023), Subcutaneous Drug Development & Delivery Consortium Inc reported a deficit of $9K, with expenses exceeding revenue. The organization holds $276K in liabilities against $901K in assets (debt-to-asset ratio: 30.6%), resulting in net assets of $626K.
| Year | Revenue | Expenses | Assets | Liabilities | Officer Comp. % | |
|---|---|---|---|---|---|---|
| 2023 | $760K | $769K | $901K | $276K | — | — |
| 2022 | $406K | $538K | $686K | $51K | — | View 990 |
| 2021 | $600K | $280K | $868K | $102K | — | View 990 |
| 2020 | $500K | $53K | $727K | $280K | — | View 990 |
Year-by-Year Financial Summary
- 2023: Revenue of $760K, expenses of $769K, and assets of $901K (revenue +87.1% year-over-year).
- 2022: Revenue of $406K, expenses of $538K, and assets of $686K (revenue -32.3% year-over-year).
- 2021: Revenue of $600K, expenses of $280K, and assets of $868K (revenue +20.0% year-over-year).
- 2020: Revenue of $500K, expenses of $53K, and assets of $727K.
View Individual Filing Years
Explore detailed financial data from each IRS 990 filing year for Subcutaneous Drug Development & Delivery Consortium Inc:
Data Sources and Methodology
This transparency report for Subcutaneous Drug Development & Delivery Consortium Inc is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.
IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.
Disclaimer
AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.